1-Methyl-4-{3-[3-(methyloxy)-4-nitrophenyl]-2-propyn-1-yl}piperazine → 2-(Methyloxy)-4-[3-(4-methyl-1-piperazinyl)propyl]aniline
反応式
[CH3:1][N:2]1[CH2:7][CH2:6][N:5]([CH2:8][C:9]#[C:10][C:11]2[CH:16]=[CH:15][C:14]([N+:17]([O-])=O)=[C:13]([O:20][CH3:21])[CH:12]=2)[CH2:4][CH2:3]1>CCOC(C)=O.CO>[CH3:21][O:20][C:13]1[CH:12]=[C:11]([CH2:10][CH2:9][CH2:8][N:5]2[CH2:6][CH2:7][N:2]([CH3:1])[CH2:3][CH2:4]2)[CH:16]=[CH:15][C:14]=1[NH2:17]参加物
3
実験手順
1-methyl-4-{3-[3-(methyloxy)-4-nitrophenyl]-2-propyn-1-yl}piperazine (0.309 g, 1.07 mmol) was placed in a 40 mL high vial and dissolved in 10 mL of 1 to 1 EtOAc/MeOH. 5 wt % Platinum(sulfided)/carbon (0.291 g, 0.075 mmol) was added followed quickly by a screw cap septum. The vial was evacuated and filled with N2 six times to remove any oxygen. The vial was then pressurized with H2 (balloon). The solution stirred overnight. The next morning the vessel was evacuated and filled with N2 six times to remove any H2. The solution was filtered through celite and evaporated to afford the title compound of step B (0.165 mg, 0.63 mmol, 60%). 1H NMR (400 MHz, CDCl3) δ ppm 6.55-6.64 (m, 3H), 3.83 (s, 3H), 3.56 (bs, 2H), 2.47-2.56 (m, 8H), 2.36-2.41 (m, 2H), 2.31 (s, 3H), 1.75-1.83 (m, 1H), 1.53-1.64 (m, 1H), 0.92 (t, J=7.42 Hz, 2H).